Advertisement

Topics

Karolinska Development and Axelar Company Profile

14:24 EST 21st November 2017 | BioPortfolio

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com


News Articles [93 Associated News Articles listed on BioPortfolio]

Karolinska Development: Investing in innovative business

Jim Van Heusden of Karolinska speaks to Fintan Walton of PharmaVentures about his strategy for the company’s growth, his ambitions for investment opportunities outside Sweden, and the challenges and...

Karolinska Development AB (publ): Karolinska Development realizes value increase in the portfolio company BioArctic through a partial exit and receives SEK 35 million

STOCKHOLM 6 November 2017. Karolinska Development today announces that the company has sold 1.5 million shares to a total amount of SEK 35 million in the portfolio company BioArctic Neurosciences ...

Karolinska to own 7.7% of Xspray Pharma after listing

Nordic life sciences investment firm Karolinska Development is set to receive a significant chunk of…

Karolinska Development AB Umecrine Cognition Appoints Dr. To Its Board Of Directors

STOCKHOLM - September 5, 2017. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development with a novel GABAA receptor modulator for the treat...

Feinstein, Karolinska license rights to start-up Applied Immunotherapeutics

The Feinstein Institute for Medical Research and Karolinska Institute granted Applied Immunotherapeutics Inc. (start-up developing treatments for autoimmune and inflammatory diseases) rights to discov...

Karolinska Development AB ??? Interim Report (January-June 2017) ??? Invitation To Conference Call And Webcast

STOCKHOLM - August 24, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) will publish its Interim Report - January-June 2017 on August 29, 2017 after market closure. The company will also ho...

Are Scientific Articles Less Reader Friendly Now? Karolinska Researchers Say Yes.

In this article from Karolinska Institute, investigators analyzed scientific articles published from 1881 to 2015, and determined science is becoming less readable over time.  Agree, disagree? Le...

Karolinska Development AB's Portfolio Company Umecrine Cognition Secures Financing For Clinical Development Of The Drug Candidate GR3027 Against Sleep Disorders

  Life Sciences Jobs   ...

Drugs and Medications [0 Results]

None

PubMed Articles [773 Associated PubMed Articles listed on BioPortfolio]

Sleep quality after modified uvulopalatopharyngoplasty: Results from the SKUP3 randomized controlled trial.

To investigate whether uvulopalatopharyngoplasty (UPPP) improves sleep quality in patients with Obstructive Sleep Apnea (OSA) using the Functional Outcomes of Sleep Questionnaire (FOSQ) and the Karoli...

Facilitating NPDP Role Development: One Healthcare System's Experience.

Transitioning into the Nursing Professional Development Practitioner role requires development of new knowledge and competencies, which takes time and resources. One healthcare system took advantage o...

Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.

Understanding the drug development pathway is critical for streamlining the development of effective cancer treatments. The objective of the current study was to delineate the drug development timelin...

Product Development and Commercialization of Diagnostic or Life Science Products for Scientists and Researchers.

Commercializing a diagnostic or life science product often encompasses different goals than that of research and grant funding. There are several necessary steps, and a strategy needs to be well defin...

Harnessing the Power of Learning Management Systems: An E-Learning Approach for Professional Development.

E-learning provides an alternative approach to traditional professional development activities. A learning management system may help nursing professional development practitioners deliver content mor...

Clinical Trials [1490 Associated Clinical Trials listed on BioPortfolio]

Choline Supplementation During Pregnancy: Impact on Attention and Social Withdrawal

The goal is to determine if providing a nutritional supplement, phosphatidylcholine, to pregnant women improves early brain development with improved brain-related development during the f...

Valve Leaflet Motion in Sutureless Bioprosthetic Aortic Valves

A single-center prospective interventional trial. Patients implanted with a sutureless bioprosthetic aortic valve at Karolinska University Hospital in Stockholm, Sweden from 2012 will be e...

Zinc and Biobehavioral Development in Early Childhood

Zinc is necessary for growth and development, including the central nervous system, and zinc deficiency which is common in resource-poor settings, may adversely affect social, behavorial, ...

Correlation of Volumetric Brain Analysis With Development at 18 Months

The study will correlate the volumes of the brain obtained from magnetic resonance imaging (MRI) scans done at term gestation for infants born prematurely who weighed less than 1000 grams ...

Developmental Effects of Infant Formula Supplemented With LCPUFA

The purpose of this study is to compare the effects on visual development, growth, cognitive development, tolerance, and blood chemistry parameters in term infants fed one of four study fo...

Companies [470 Associated Companies listed on BioPortfolio]

Karolinska Development AB and Axelar AB

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique business model, the company cost efficiently guides the commercialization of world ...

Karolinska Development and Axelar

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercializa...

Karolinska Development AB PUBL

Managing one of the largest portfolios of life science research companies in Europe, Karolinska Development AB is a new type of company focused on filling the innovation gap within the pharmaceuti...

Karolinska Development AB (publ), and BioChromix AB

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Karolinska Development AB and Uminova Invest AB

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

More Information about "Karolinska Development and Axelar" on BioPortfolio

We have published hundreds of Karolinska Development and Axelar news stories on BioPortfolio along with dozens of Karolinska Development and Axelar Clinical Trials and PubMed Articles about Karolinska Development and Axelar for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Karolinska Development and Axelar Companies in our database. You can also find out about relevant Karolinska Development and Axelar Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record